Étude pancanadienne de surveillance moléculaire du myélome multiple menée par l’Institut de recherche Terry Fox
NCI M4
NCT03421132
 Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
 PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Autres |
Nathalie Lachapelle
514-252-3400 poste 4471
|
(EN) A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Actif en recrutement
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
|
Nathalie Lachapelle
514-252-3400 poste 4471
|
(EN) A phase 1B, open-label study of Elranatamab in combination with Iberdomide in participants with relapsed refractory multiple myeloma
MagnetisMM-30 (C1071030)
NCT06215118
Actif en recrutement
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
|
Christine Lawson
819-346-1110 poste 12942
|
(EN) A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Marie-Anne Capobianco
514-338-2222 poste 3493
|
(EN) A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
(EN) A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
64007957MMY1003
NCT04586426
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
(EN) A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
TED18162
NCT06630806
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
(EN) Elranatamab post trial access: an open-label, single-arm study for participants with multiple myeloma continuing from Pfizer-sponsored Elranatamab clinical studies
MagnetisMM15
NCT06057402
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
(EN) A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
iMMagine-3
NCT06413498
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Nancy Renouf
514-934-1934 poste 35718
|
(EN) A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma
SUCCESSOR-1
NCT05519085
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
|
Marie-Anne Capobianco
514-338-2222 poste 3493
|
Groupe d'étude en oncologie du Québec